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The SARS-CoV-2 pandemic is the last in line of several epidemics of infectious 
diseases that have been linked to the Guillain-Barré syndrome (GBS). As threats 
of epidemics of emerging infectious diseases persist, this is the time to learn 
from the past and to advance our response to future outbreaks in terms of 
research and management of GBS.
In the past decade, the world confronted 
several pandemics of emerging infec-
tious diseases including Zika virus and 
most recently Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS- CoV-2). 
One of the neurological complications 
reported in relation to these infectious 
diseases is the Guillain- Barré syndrome 
(GBS), a rapidly progressive immune- 
mediated polyradiculoneuropathy that can 
cause paresis in all limbs, cranial and respi-
ratory muscles.1–3 Approximately 20% 
require admission at an intensive care unit 
(ICU), and 2%–12% die, depending on the 
care available.4
In the past, research responses inves-
tigating a possible link between GBS 
and outbreaks of infectious diseases or 
vaccines have been delayed. This is prob-
lematic as healthcare institutions need 
to be able to prepare for increased inci-
dences in patients with GBS, and public 
health personnel need to identify any 
possible mitigating factors. History now 
seems to repeat itself when case reports of 
SARS- CoV-2- related GBS are mounting, 
and disquiet over a possible association 
increases. As threats of epidemics of 
emerging infectious diseases persist, this 
is the time to learn from the past and to 
advance our response to future outbreaks 
in terms of research and management of 
GBS.
CHALLENGES AND PROSPECTS IN 
RESEARCH PREPAREDNESS
The first aims when studying a possible 
link between an infectious agent and 
GBS are to determine if a true associa-
tion exists and to determine the impact in 
terms of frequency and severity. During 
an outbreak, observational cohorts are 
set up rapidly by clinicians, some of 
whom may lack experience in diagnosing 
and managing GBS due to the need to 
quickly mobilise personnel. These studies 
are often done at a single centre and not 
harmonised with GBS research from other 
centres, which can result in missing out of 
important clinical information.
How can one ensure a high- quality study 
within the limited time frame afforded 
by an infectious disease epidemic? Many 
hurdles must be overcome before recruit-
ment can be started, and accurate and 
sufficient data collection is complex. 
Here, we list the most important hurdles 
and provide suggestions on how to deal 
with them.
Study design: surveillance and case–
control studies
To determine the impact in terms of 
frequency, a reliable and international 
surveillance platform for GBS incidence 
during and between epidemics, either 
active or passive, should be in place to 
define the background incidence and to 
detect an increase in cases. A surveillance 
system for acute flaccid paralysis (AFP) in 
children under the age of 15 was set up 
to eradicate polio and is operative globally 
(http:// polioeradication. org/). The inter-
national community may benefit from 
introducing AFP surveillance for all ages 
or for GBS specifically.
To determine an association between 
GBS and an infectious agent, a cohort 
study with a case–control design is neces-
sary. A predefined research protocol 
should be developed that is feasible in 
different healthcare infrastructures and 
easy to activate and use, to ensure a 
high- quality study within a limited time 
frame. Critical requirements for the study 
include clear case definitions for GBS and 
the collection of data on the clinical and 
electrophysiological phenotype, as this 
can be associated with a specific infec-
tious agent and may provide evidence of 
an association. To study the impact for 
patients, outcome of at least 6–12 months 
with validated outcome measures should 
be recorded.
Such a protocol would be supported 
by a network of neurologists, such as the 
Inflammatory Neuropathy Consortium 
of the Peripheral Nerve Society, and can 
be based on the protocol of the Interna-
tional GBS Outcome Study, that is running 
in 19 countries and is also used by other 
research groups.5 6 Existing networks such 
as The Global Health Network could help 
to make the existence of such a protocol 
widely known.7 Inspiration can be drawn 
from large international research consortia 
on infectious diseases, such as the Inter-
national Severe Acute Respiratory and 
emerging Infection Consortium (ISARIC) 
and the Platform for European Prepared-
ness Against (Re- )emerging Epidemics 
(PREPARE) that assure and prepare an 
agile research response to outbreak- prone 
infectious diseases (https://www. prepare- 
europe. eu/; https:// isaric. tghn. org/).
Funding application and ethical 
permission
The time between application and receipt 
of funding and between submission and 
acceptance by an ethical review board is 
usually several months.8 9 This sequential 
process therefore often leads to signif-
icant delays. A recent example is the 
Zika virus pandemic that peaked at the 
beginning of 2016 when WHO declared 
it a Public Health Emergency of Inter-
national Concern. By the time the Zika 
virus research consortia could initiate 
their work with funding from the Euro-
pean Union in October 2016, the peak 
of the epidemic had passed, and most 
participating researchers still needed to go 
through ethical approval10 (figure 1).
Fortunately, there are already initiatives 
in place to accelerate the process of grant 
application and ethical review during an 
outbreak. The Global Research Collabo-
ration for Infectious Disease Preparedness 
(GLOPID- R) joins together major public 
and private research funding organisations 
to facilitate the mobilisation of resources 
and the immediate start of critical research 
in an outbreak situation (https://www. 
glopid- r. org/).11 12 Legal, ethical, logistical 
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and administrative barriers that delay a 
research response at the peak of a health 
crisis could be addressed by making 
funding available during interpandemic 
periods, which can be used to develop 
standardised study protocols and research 
networks, with an additional budget to 
support infrastructure when the next 
outbreak occurs.
The idea of a ‘central’ or ‘universal’ 
institutional review board (IRB) in 
which institutional review could be fast- 
tracked in situations of emergent infec-
tious diseases has recently been launched 
by the National Institutes of Health. 
Furthermore, in some jurisdictions, events 
of public health emergency can bypass 
complete IRB approval, thus shortening 
the time to implementation.13 14
Collecting and sharing data and 
biosamples
As GBS is a rare disease (1–2 per 100 000 
per year), a multicentre or even multina-
tional approach is generally necessary to 
capture a sufficient number of cases to 
provide evidence of an association and 
describe the clinical phenotype.15 Setting 
up a multicentre study is time- consuming, 
and increasingly complex privacy regula-
tions further restrict the sharing of data 
and biosamples between institutions. 
Operational consortia allow for the 
continued multicentre collection of data 
and samples during an epidemic, although 
sharing of biosamples often still requires 
material transfer agreements. Having 
preapproved protocols and agreements 
ready for use upfront could accelerate this 
process.
CHALLENGES AND OPPORTUNITIES IN 
DIAGNOSIS AND MANAGEMENT
In case of a sudden increase in patients 
with GBS, clinicians with limited exper-
tise in GBS may need to manage these 
patients, and availability of facilities and 
resources may run out. We expect limita-
tions mainly in ICU beds and rehabilita-
tion care, as this was also reported during 
the Zika virus outbreak in Brazil.16 These 
limitations are especially important in low- 
resource countries that often have subop-
timal or malfunctional healthcare systems, 
a lack of health professionals and are hot 
spots for outbreaks of emerging infectious 
diseases.17 Here, we provide recommen-
dations on how to safeguard good quality 
diagnosis and management of GBS during 
a pandemic.
Guideline for management of GBS
Diagnosis, treatment and monitoring of 
GBS can be complicated as patients may 
present with non- specific symptoms and 
vary with respect to clinical severity, treat-
ment response and outcome.18 Further-
more, there are several diseases that can 
be difficult to distinguish from GBS, such 
as critical illness neuropathy, which is now 
especially important as many patients are 
admitted to the ICU for extended periods 
of time due to coronavirus disease 2019 
(COVID-19). Recently a 10- step evidence- 
based consensus guideline for GBS was 
developed in response to the Zika virus 
outbreak.19 This guideline was designed 
to be compact and easy- to- use and appli-
cable in all healthcare settings. An online 
version of the guideline is supported by 
The Global Health Network (https:// rede. 
tghn. org/ gbs- flowchart- sample/ introduc-
tion- gbs/). Its use may help improve the 
management of GBS during an outbreak.
Availability of resources
The two proven effective therapeutics for 
GBS, intravenous immunoglobulin (IVIg) 
and plasmapheresis, are expensive, and 
unaffordable for many patients in low- 
resource countries. Furthermore, demand 
for IVIg has tripled in the past decades, 
and shortages may occur in times of 
crisis.20 21 New and affordable treatment 
options for GBS are therefore warranted. 
A pilot study on small volume plasma 
exchange showed potential, but the ther-
apeutic efficacy needs to be determined.22
The COVID-19 pandemic has made 
it apparent that upscaling availability 
of ICU beds is necessary to prepare for 
future outbreaks of infectious diseases 
that cause acute respiratory distress. 
Prediction models for respiratory failure 
in patients with GBS, such as the Erasmus 
GBS Respiratory Insufficiency Score, may 
further relieve pressure from ICU facilities 
but need to be validated in non- Western 
countries.23 Now that more patients are 
recovering from COVID-19, lack of care-
takers and beds in rehabilitation units is 
also increasingly becoming a problem.24 
Upscaling availability is imperative to cope 
with this new wave of patients and will 
also be of use in a future outbreak of GBS.
CONCLUSION
In the past decade, multiple pandemics 
of infectious diseases have been linked to 
increased incidence of GBS. Epidemics 
will continue to occur, and it is vital to 
advance preparedness in research and clin-
ical management of GBS in an outbreak 
setting.
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